S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:PHVS

Pharvaris Stock Forecast, Price & News

$28.75
-4.86 (-14.46 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.14
Now: $28.75
$34.62
50-Day Range N/A
52-Week Range
$23.06
Now: $28.75
$42.86
Volume139,847 shs
Average Volume186,676 shs
Market Capitalization$915.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHVS
CUSIPN/A
CIKN/A
Phone31 71 203 6410
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$915.40 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.44 out of 5 stars

Medical Sector

585th out of 1,972 stocks

Biotechnology Industry

20th out of 125 stocks

Analyst Opinion: 3.4Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$28.75
-4.86 (-14.46 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHVS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pharvaris (NASDAQ:PHVS) Frequently Asked Questions

Is Pharvaris a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pharvaris stock.
View analyst ratings for Pharvaris
or view top-rated stocks.

What stocks does MarketBeat like better than Pharvaris?

Wall Street analysts have given Pharvaris a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pharvaris wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for PHVS?

4 analysts have issued 12 month target prices for Pharvaris' shares. Their forecasts range from $41.00 to $51.00. On average, they anticipate Pharvaris' stock price to reach $47.50 in the next year. This suggests a possible upside of 65.2% from the stock's current price.
View analysts' price targets for Pharvaris
or view top-rated stocks among Wall Street analysts.

Who are Pharvaris' key executives?

Pharvaris' management team includes the following people:
  • Mr. Berndt A. E. Modig M.B.A., MBA, CPA, CEO & Exec. Director (Age 62)
  • Ms. Anna Nijdam M.Sc., R.A., Fin. Director & Principal Accounting Officer (Age 39)
  • Dr. Jochen Knolle, Chief Scientific Officer & COO (Age 71)
  • Dr. Peng Lu M.D., Ph.D., Chief Medical Officer (Age 43)
  • Dr. Anne Lesage Ph.D., Chief Early Devel. Officer (Age 59)
  • Mr. Morgan Conn Ph.D., Chief Bus. Officer (Age 52)

Who are some of Pharvaris' key competitors?

When did Pharvaris IPO?

(PHVS) raised $126 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

What is Pharvaris' stock symbol?

Pharvaris trades on the NASDAQ under the ticker symbol "PHVS."

When does Pharvaris' quiet period expire?

Pharvaris' quiet period expires on Wednesday, March 17th. Pharvaris had issued 8,270,500 shares in its initial public offering on February 5th. The total size of the offering was $165,410,000 based on an initial share price of $20.00. During Pharvaris' quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Pharvaris?

Shares of PHVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharvaris' stock price today?

One share of PHVS stock can currently be purchased for approximately $28.75.

How much money does Pharvaris make?

Pharvaris has a market capitalization of $915.40 million.

What is Pharvaris' official website?

The official website for Pharvaris is www.pharvaris.com.

How can I contact Pharvaris?

The company can be reached via phone at 31 71 203 6410.


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.